


6-Gingerol



[Gauthier et al., *Biomed Chromatogr.* 2011 Feb 18. DIO: 10.1002/bmc.1585.]

【化合物】 6-Gingerol

【測定機器】 HPLC; LC-MS/MS

【対象】 ヒト [Zick et al., *Cancer Epidemiol Biomarkers Prev.* **17**: 1930–1936 (2008)]; ラット [Gauthier et al., *Biomed Chromatogr.* 2011 Feb 18. DIO: 10.1002/bmc.1585.]

【代謝実験】 ① 被験者に Pure Encapsulation's ginger を投与した後、経時的に血清中の gingerol および shogaol 化合物濃度を HPLC で分析した。[Zick et al., *Cancer Epidemiol Biomarkers Prev.* **17**: 1930–1936 (2008)] ② ラットを用いた代謝実験: Male Sprague–Dawley rats received a single intraperitoneal dose of 40 mg/kg and rats were kept in metabolic cages. Urine and feces samples were collected over a 24 h period for the determination of [6] - gingerol excretion pathway by HPLC -MS/MS. [Gauthier et al., *Biomed Chromatogr.* 2011 Feb 18. DIO: 10.1002/bmc.1585.]

【代謝パラメータ】

Pharmacokinetic parameters of 6-gingerol and other related compounds

	1000 mg (N=6)	1500 mg (N=3)	2000 mg (N=8)
AUC (μ g/L)	12.6 ± 6.4	75.6 ± 110.3	65.6 ± 44.4
$C_{\max}$ (μ g/L)	0.4 ± 0.2	1.69 ± 2.31	0.85 ± 0.43
$t_{1/2}$ min			110.0 ± 34.9
$t_{\max}$ min	55.0 ± 7.7	60.0 ± 0.0	65.6 ± 22.6

Mean $\pm$ SD

Pharmacokinetic parameters of 8-gingerol and other related compounds

	1000 mg (N=6)	1500 mg (N=3)	2000 mg (N=8)
AUC (μ g/L)	2.1 ± 2.2	2.6 ± 2.0	18.1 ± 20.3
$C_{\max}$ (μ g/L)	0.1 ± 0.1	0.1 ± 0.1	0.23 ± 0.16
$t_{1/2}$ min			113.5 ± 41.1
$t_{\max}$ min	52.5 ± 8.7	60.0 ± 0.0	73.1 ± 29.4

Mean $\pm$ SD

Pharmacokinetic parameters of 10-gingerol and other related compounds

	1000 mg (N=6)	1500 mg (N=3)	2000 mg (N=8)
AUC (μ g/L)	2.9 ± 3.2	7.7 ± 5.3	50.1 ± 49.3
$C_{\max}$ (μ g/L)	0.1 ± 0.1	0.1 ± 0.02	0.53 ± 0.4
$t_{1/2}$ min			128.7 ± 38.8
$t_{\max}$ min	60.0 ± 0.0	80.0 ± 34.6	75.0 ± 27.8

Mean $\pm$ SD

Pharmacokinetic parameters of 6-shogaol and other related compounds

	1000 mg (N=6)	1500 mg (N=3)	2000 mg (N=8)
AUC (μ g/L)	0.8 ± 1.5	1.6 ± 2.8	10.9 ± 13.0
$C_{\max}$ (μ g/L)	0.1 ± 0.1	0.04 ± 0.08	0.15 ± 0.12
$t_{1/2}$ min			120.4 ± 42.0
$t_{\max}$ min	55.0 ± 8.7	60.0 ± 0.0	65.6 ± 22.6

Mean $\pm$ SD

[Zick et al., *Cancer Epidemiol Biomarkers Prev.* **17**: 1930–1936 (2008)]

Estimated plasma pharmacokinetic parameters after single oral administration of 2.0 g ginger extracts

	Gingerol free	6-Gingerol glucuronide	6-Gingerol sulfate
AUC_{0-t} (μ g h/mL)	N/A	0.74 ± 0.56	0.43 ± 0.26
MRT_{0-t} (h)	N/A	1.61 0.34	1.77 0.34
$T_{1/2}$ (h)	N/A	1.64 0.88	1.79 0.99
T_{max} (h)	N/A	1.03 ± 0.41	1.03 ± 0.41
C_{max} (μ g/mL)	N/A	0.45 0.25	0.26 ± 0.13
CL/F (L h ⁻¹ kg ⁻¹)	N/A	1.32 ± 0.58	1.77 ± 0.84

[Yu et al., *The American Association of Pharmaceutical Scientists Journal* 2011, DOI: 10.1208/s12248-011-9286-5]

【参考文献】

Yanke Yu, Suzanna Zick, Xiaoqin Li, Peng Zou, Benjamin Wright, and Duxin Sun, Examination of the pharmacokinetics of active ingredients of ginger in humans. *The American Association of Pharmaceutical Scientists Journal* 2011, DOI: 10.1208/s12248-011-9286-5

Marie -Lou Gauthier, Jennifer Douat, Pascal Vachon and Francis Beaudry
Characterization of [6] -gingerol metabolism in rat by liquid chromatography electrospray tandem mass spectrometry. *Biomed Chromatogr.* 2011 Feb 18. DOI: 10.1002/bmc.1585.

Suzanna M. Zick, Zora Djuric, Mack T. Ruffin, Amie J. Litzinger, Daniel P. Normolle, Meihua Rose Feng, and Dean E. Brenner, Pharmacokinetics of 6-, 8-, 10-gingerols and 6-shogaol and conjugate metabolites in healthy human subjects. *Cancer Epidemiol Biomarkers Prev.* **17**: 1930–1936 (2008). DOI: 10.1158/1055-9965.EPI-07-2934.